01 — At a Glance
Africa’s Pharmacy Is Listed in Mumbai, And It Just Had a Wild Quarter
- 52-Week High / Low₹244 / ₹105
- Q3 FY26 Revenue₹218 Cr
- Q3 FY26 PAT₹25 Cr
- Q3 FY26 EPS₹2.20
- TTM EPS₹10.33
- Book Value₹107
- Price to Book2.01x
- Dividend Yield0.23%
- Debt / Equity0.05x
- 3-Month Return+26.5%
Opening Bell: Bliss GVS Pharma is a ₹2,270 crore pharma company that earns 93% of its revenues from exports — primarily to sub-Saharan Africa. The stock has returned 71% in one year, 26.5% in three months, and 40% over three years. Q3 FY26 revenue of ₹218 Cr is up 3.7% YoY. PAT at ₹25 Cr looks modest but the TTM picture at ₹114 Cr tells a much better story. Oh, and the company is currently on its third leadership configuration in under five months. Your mechanic changes oil less frequently than Bliss GVS changes CEOs.
02 — Introduction
Suppositories, Sub-Saharan Africa, and a Very Eventful Quarter
Let’s be honest — when most Indian investors think pharma, they think Sun Pharma’s USFDA troubles, Cipla’s new launches, or whichever generic company just struck a deal in the US. Nobody wakes up thinking, “I should investigate the anti-malarial suppository export market.” And yet, here we are — talking about a company that has quietly built a dominant franchise across 60+ countries, earns nearly all its revenue from exports, and just gave its investors a 71% return in twelve months.
Bliss GVS Pharma, incorporated in 1984 in Mumbai, is India’s first EU-GMP certified suppository manufacturer. That’s a niche so specific that their competition is largely themselves. The company sells anti-malarial, anti-fungal, anti-bacterial, and anti-inflammatory formulations across 60+ therapeutic segments — in forms that most Indian investors politely decline to google.
The CY2025 Q3 result (nine months ending December 2025) is technically a “Quarterly Results” declaration for Q3 FY26 on the Indian fiscal calendar. Revenue grew a steady 3.7% YoY to ₹218 Cr. PAT came in at ₹25 Cr. Nothing dramatic in the numbers. The drama was entirely off-balance-sheet: an MD resigned, a promoter became CEO, the company denied a CNBC merger rumour, received a GST notice, won a trademark case, and got a USFDA approval — all within five months. Boring earnings. Extremely lively boardroom.
Fun Fact: Bliss GVS contract manufactures suppositories for Sun Pharma and Mankind — two companies worth multiples of Bliss. When the giants outsource their embarrassing products to you, that’s niche moat energy.
03 — Business Model: WTF Do They Even Do?
They Make Pills and Suppositories. For Africa. Via Mumbai. Profitably.
Strip away the polite corporate language and here’s what Bliss GVS actually does: they make medicines in unusual dosage forms (suppositories, pessaries, capsules, tablets, syrups) at facilities in Palghar, Ambernath, and two plants in Nigeria — and sell them predominantly across sub-Saharan Africa. Their flagship products — P-Alaxin, Lonart (WHO-endorsed anti-malarial), Funbact, and Lofnac — are market leaders in their categories across the continent.
About 65% of revenue comes from Africa (down from 69% in FY24 — they’re trying, slowly, to diversify). Another 28% comes from other export markets. Domestic India? A charming 7% rounding error. The company contracts with Sun Pharma, Mankind, Sanofi, and Alkem for domestic manufacturing — those clients helpfully cannot export, so no competition from them internationally.
They have 150+ branded formulations across 60+ therapeutic segments. Seven manufacturing units. Capacity for 680 million tablet units, 380 million suppository/pessary units, plus sachets, capsules, creams, and more. The Palghar expansion adding ~200 mn semi-solid units is expected by Q4 FY26. Solar capacity is being doubled. This is a company quietly investing in infrastructure while the stock price delivers fireworks.
Export Share93%of Total Sales
Africa Revenue~65%of Total Revenue
Countries60+Export Markets
Brands150+Formulations
Royalty Note: Unlike some MNC pharma subsidiaries, Bliss GVS does not pay a royalty to a foreign parent — because Bliss IS the parent for all intents and purposes in this segment. This is an Indian-promoted company that built global reach from scratch. Quietly impressive, particularly given that their CRISIL credit rating was in “Issuer Not Cooperating” territory just three years ago and has since been upgraded to BBB+/Stable.
💬 Drop a comment: Did you know India’s first EU-GMP certified suppository manufacturer is a BSE-listed company? Do you think Africa-focused pharma companies deserve higher valuations from Indian markets?
04 — Financials Overview
Q3 FY26: The Numbers (Consolidated, ₹ Crores)
Continue reading with a premium membership.
